Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor

Protocol Title: A Phase II open label, umbrella study evaluating the efficacy and safety of Fulvestrant plus DNA damage repair inhibitors in hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor

Trial Details

NCT ID
NCT05536128
Phase
PHASE2
Sponsor
Seoul National University Hospital
Status
RECRUITING
Cancer Type
ER/PR Positive (Hormone Receptor Positive) Breast Cancer
Interventions
  • Olaparib
  • Fulvestrant
Locations (sample)
  • Seoul, South Korea|37.566,126.9784

Key Eligibility Criteria

  • Patients are eligible to be included in the study only if all of the following inclusion criteria and none of the exclusion criteria apply:
  • Informed consent
  • Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF…
  • Provision of signed and dated, written informed consent form prior to any mandatory study specific procedures, sampling, and analyses.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find ER/PR Positive (Hormone Receptor Positive) Breast Cancer Trials on Trialify →